[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564250":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin arm","EXPERIMENTAL","Participants will take Dapagliflozin10mg every day in -1 to 14 days.",[13],"Drug: Dapagliflozin (DAPA)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Dapagliflozin (DAPA)","Participants will take Dapagliflozin 10mg every day in -1 to 14 days",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Yang XU","CONTACT","86-0512-67781850","xuyang1020@126.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Biqi ZHOU","86-0512-67781856","zbq0903@126.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Suzhou","Jiangsu","215000","China","CN",{"type":40,"coordinates":41},"Point",[42,43],120.59538,31.30408,{"lat":43,"lon":42},[46],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100564250","phase-2-dapagliflozin-in-allo-hct-for-agvhd-100564250",false,"NCT06626737","Dapagliflozin in Allo-HCT for aGVHD","Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study","DAPALAG-01","Inclusion Criteria:\n\n* Age 18 to 65 years old.\n* Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor.\n* Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin A and methotrexate.\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n* Patients with prior use of Dapagliflozin or other hypoglycemic medications may switch to Dapagliflozin, contingent upon the treating physician's assessment of contraindications, will be eligible.\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures.\n\nExclusion Criteria:\n\n* With other malignancies.\n* With a previous history of autologous hematopoietic cell transplantation, allo-HCT or chimeric antigen receptor T-cell therapy.\n* With a history of allergies to Dapagliflozin.\n* With type 1 diabetes or a history of ketoacidosis.\n* With a history of recurrent urinary tract infections.\n* With severe organ dysfunction.\n* With active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection.\n* In pregnancy or lactation period.\n* With any conditions not suitable for the trial (investigators' decision).","ALL","18 Years","65 Years",{"count":61,"type":62},72,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.",[68],"Graft-versus-host Disease (GVHD)",[70,71,72],"Dapagliflozin","Graft-versus-host disease","Allogeneic hematopoietic cell transplantation","2025-06-02",{"date":75,"type":76},"2025-06-05","ACTUAL",{"date":78,"type":76},"2025-04-26",{"date":80,"type":62},"2026-12-31",{"name":5,"class":6},1]